Stefan Kiesgen

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Antibody-drug conjugates (ADCs) have evolved as a new class of potent cancer therapeutics. We here report on the development of ADCs with specificity for the B-cell lineage specific (surface) antigen CD22 being expressed in the majority of hematological malignancies. As targeting moiety a previously generated humanized anti-CD22 single-chain variable(More)
  • 1